MD20150121A2 - Derivaţi de benzimidazol ca inhibitori ai bromodomeniului - Google Patents

Derivaţi de benzimidazol ca inhibitori ai bromodomeniului

Info

Publication number
MD20150121A2
MD20150121A2 MDA20150121A MD20150121A MD20150121A2 MD 20150121 A2 MD20150121 A2 MD 20150121A2 MD A20150121 A MDA20150121 A MD A20150121A MD 20150121 A MD20150121 A MD 20150121A MD 20150121 A2 MD20150121 A2 MD 20150121A2
Authority
MD
Moldova
Prior art keywords
compounds
benzimidazole derivatives
bromodomain inhibitors
bromodomain
inhibitors
Prior art date
Application number
MDA20150121A
Other languages
English (en)
Russian (ru)
Other versions
MD4592B1 (ro
Inventor
Евангелос АКТОУДИАНАКИС
Грегори ЧИНЬ
Бриттон Кеннет Корки
Цзиньфа Ду
Кристина Элбел
Роберт Х. Цзян
Тецуя Кобаяси
Р Ли
Рубен Мартинес
Сэмюель Е. МЕТОБО
Майкл Миш
Мануэль МУНЬОС
Софи Шевик
Дэвид Сперандио
Х Ян
Джефф ЗАБЛОКИ
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20150121A2 publication Critical patent/MD20150121A2/ro
Publication of MD4592B1 publication Critical patent/MD4592B1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Invenţia se referă la compuşi chimici care pot acţiona ca inhibitori sau care altfel pot modula activitatea proteinei conţinând bromodomeniu, inclusiv a proteinei conţinând bromodomeniul 4 (BRD4), precum şi la compoziţii şi formulări care conţin astfel de compuşi şi metode de obţinere şi utilizare a unor astfel de compuşi. Compuşii includ compuşi cu Formula (I)(I)în care R1a, R1b, R2a, R2b, R3, R4a, R4b şi R5 sunt descrişi în prezentul document.
MDA20150121A 2013-05-09 2014-05-08 Derivaţi de benzimidazol ca inhibitori ai bromodomeniului MD4592B1 (ro)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361821612P 2013-05-09 2013-05-09
US201361826912P 2013-05-23 2013-05-23
US201361860229P 2013-07-30 2013-07-30
US201461951347P 2014-03-11 2014-03-11
PCT/US2014/037344 WO2014182929A1 (en) 2013-05-09 2014-05-08 Benzimidazole derivatives as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
MD20150121A2 true MD20150121A2 (ro) 2016-05-31
MD4592B1 MD4592B1 (ro) 2018-09-30

Family

ID=50897952

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150121A MD4592B1 (ro) 2013-05-09 2014-05-08 Derivaţi de benzimidazol ca inhibitori ai bromodomeniului

Country Status (26)

Country Link
US (4) US9458145B2 (ro)
EP (1) EP2994469B1 (ro)
JP (1) JP6049942B2 (ro)
KR (1) KR101761049B1 (ro)
CN (1) CN105324379B (ro)
AP (1) AP2015008869A0 (ro)
AR (1) AR096246A1 (ro)
AU (1) AU2014262622B2 (ro)
BR (1) BR112015028017A2 (ro)
CA (1) CA2911408C (ro)
CL (1) CL2015003280A1 (ro)
CR (1) CR20150639A (ro)
EA (1) EA029091B1 (ro)
ES (1) ES2710120T3 (ro)
HK (2) HK1219278A1 (ro)
MD (1) MD4592B1 (ro)
MX (1) MX2015015478A (ro)
NZ (1) NZ713718A (ro)
PE (1) PE20160029A1 (ro)
PH (1) PH12015502534A1 (ro)
PT (1) PT2994469T (ro)
SG (1) SG11201509220XA (ro)
TW (1) TWI527811B (ro)
UA (1) UA112618C2 (ro)
UY (1) UY35559A (ro)
WO (1) WO2014182929A1 (ro)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
ES2755827T3 (es) 2013-03-15 2020-04-23 Incyte Holdings Corp Heterciclos tricíclicos como inhibidores de proteína BET
CA2915622C (en) * 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
LT3674302T (lt) 2014-04-23 2023-06-12 Incyte Holdings Corporation 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai kaip bet baltymų inhibitoriai
EP3177604A1 (en) 2014-08-05 2017-06-14 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
EP3194406B8 (en) * 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966452A1 (en) * 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN104788441A (zh) * 2015-04-02 2015-07-22 湖南华腾制药有限公司 一种多取代苯并恶唑衍生物的制备方法
GB201506658D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN107849024A (zh) * 2015-05-15 2018-03-27 吉利德科学公司 具有作为吲哚胺2,3‑二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
EP3298005B1 (en) * 2015-05-21 2024-01-24 The Regents of The University of California Anti-cancer compounds
MY195977A (en) * 2015-09-21 2023-02-27 Plexxikon Inc Heterocyclic Compounds and uses Thereof
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
CN108727276A (zh) * 2015-12-01 2018-11-02 江苏理工学院 苯并咪唑衍生物的制备方法
EP3394044A1 (en) 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
CN108883311A (zh) * 2015-12-24 2018-11-23 赛尔基因昆蒂赛尔研究公司 布罗莫结构域和额外末端蛋白抑制剂组合疗法
PT3472157T (pt) 2016-06-20 2023-05-30 Incyte Corp Formas sólidas cristalinas de um inibidor bet
CN109843874B (zh) 2016-06-24 2022-05-27 加利福尼亚大学董事会 作为parp1、parp2和/或微管蛋白的抑制剂可用于治疗癌症的酞嗪衍生物
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
AU2017347853B2 (en) * 2016-10-27 2022-02-17 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018097976A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
US20180141939A1 (en) 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
WO2018106433A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent
MX2019006821A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
CN108314680A (zh) * 2017-01-16 2018-07-24 凯惠科技发展(上海)有限公司 一种含芳环化合物、其制备方法、药物组合物及应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US11493520B2 (en) * 2017-05-19 2022-11-08 Epicypher, Inc. Assays for nucleosome remodeling activity
US11292791B2 (en) 2017-09-15 2022-04-05 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
WO2019120234A2 (zh) * 2017-12-20 2019-06-27 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3790487B1 (en) * 2018-05-08 2023-08-23 Boston Scientific Medical Device Limited Devices for puncturing tissue
DK3793565T3 (en) 2018-05-14 2022-03-07 Gilead Sciences Inc Mcl-1-inhibitorer
WO2020006483A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
WO2020200284A1 (zh) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BR122020010759B1 (pt) 2007-03-12 2021-06-29 Ym Biosciences Australia Pty Ltd Compostos de fenil amino pirimidina inibidores de proteína quinases, processo para a preparação do composto, composição farmacêutica, e, implante
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
WO2013055607A1 (en) * 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David S. Hewings ET AL: „Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands", Journal of Medicinal Chemistry, vol. 56, Nr. 8, 2013.04.25, p. 3217-3227 *
Duncan Hay ET AL: „The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains", MedChemComm, vol. 4, Nr. 1, 2013.01.01, p. 140 *

Also Published As

Publication number Publication date
AR096246A1 (es) 2015-12-16
EA029091B1 (ru) 2018-02-28
HK1222646A1 (zh) 2017-07-07
HK1219278A1 (zh) 2017-03-31
CR20150639A (es) 2016-01-29
US20180282316A1 (en) 2018-10-04
US9458145B2 (en) 2016-10-04
UA112618C2 (uk) 2016-09-26
PH12015502534A1 (en) 2016-02-22
PT2994469T (pt) 2019-03-18
US20160376261A1 (en) 2016-12-29
CL2015003280A1 (es) 2016-06-24
EP2994469B1 (en) 2018-12-19
WO2014182929A1 (en) 2014-11-13
ES2710120T3 (es) 2019-04-23
EP2994469A1 (en) 2016-03-16
AP2015008869A0 (en) 2015-11-30
TW201506022A (zh) 2015-02-16
MX2015015478A (es) 2016-06-14
CN105324379A (zh) 2016-02-10
US20140336190A1 (en) 2014-11-13
AU2014262622A1 (en) 2015-11-12
TWI527811B (zh) 2016-04-01
PE20160029A1 (es) 2016-02-14
KR101761049B1 (ko) 2017-07-24
KR20160008232A (ko) 2016-01-21
MD4592B1 (ro) 2018-09-30
EA201591965A1 (ru) 2016-08-31
BR112015028017A2 (pt) 2017-07-25
US10017501B2 (en) 2018-07-10
JP2016520062A (ja) 2016-07-11
AU2014262622B2 (en) 2016-08-11
US20160075695A1 (en) 2016-03-17
CN105324379B (zh) 2018-12-04
CA2911408C (en) 2017-10-24
SG11201509220XA (en) 2015-12-30
UY35559A (es) 2014-11-28
CA2911408A1 (en) 2014-11-13
NZ713718A (en) 2016-12-23
JP6049942B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
PH12015502534A1 (en) Benzimidazole derivatives as bromodomain inhibitors
PH12015502246A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MY162604A (en) Heterocyclic compounds and uses thereof
MX362550B (es) Inhibidores ciclicos de glutaminasa.
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
MX2009010984A (es) Moduladores de heterociclo cinasa de anillo fusionado.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
PH12019501359A1 (en) Polymorphs
MX2019007571A (es) Polimorfos.
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
NZ719465A (en) Quinoline derivatives as bromodomain inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
CR20200267A (es) Polimorfos
PH12015500292A1 (en) 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену
EA201101703A1 (ru) 17β-АЛКИЛ-17α-ОКСИЭСТРАТРИЕНЫ
TH166104B (th) อนุพันธ์ของเบนซิมิดาโซลที่เป็นสารยับยั้งโบรโมโดเมน
TH167410A (th) อนุพันธ์เบนซิมิดาโซโลนที่เป็นสารยับยั้งโบรโมโดเมน(Benzimidazolone Derivatives as Bromodomain Inhibitors)

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)